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Abstract
People with epilepsy have an increased risk of dying prematurely and the most common epilepsy-related category 
of death is sudden unexpected death in epilepsy (SUDEP). SUDEP is mainly a problem for patients with chronic 
uncontrolled epilepsy. The ultimate goal of research in SUDEP is to develop new methods to prevent it and actions other 
than medical and surgical therapies that could be very useful. Nutritional aspects, i.e., omega-3 fatty acids deficiency, 
could have an interesting role in this scenario. Some animal and clinical studies have suggested that omega-3 fatty 
acids could be useful in the prevention and treatment of epilepsy and hence SUDEP. It has been ascertained that the 
only foods that provide large amounts of omega-3 are seafood (fish and shellfish); however, some fish are contaminated 
with methylmercury, which may counteract the positive effects of omega-3 fatty acids. Our update review summarises 
the knowledge of the role of fish consumption on epilepsy research.
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Consumo de peixe, contaminantes e morte súbita em epilepsia:  
mais benefícios do que riscos
Resumo
Pessoas com epilepsia têm um risco aumentado de morrer de forma prematura e a causa mais comum de morte 
relacionada à epilepsia encontra-se na categoria de morte súbita inesperada em epilepsia (SUDEP). SUDEP é um 
problema significativo para pacientes com epilepsia crônica não controlada. O principal objetivo nas pesquisas em 
SUDEP é o desenvolvimento de métodos capazes de levar à sua prevenção e ações outras que não medicamentosas e 
cirúrgicas que podem ser úteis. Os aspectos nutricionais, como por exemplo, a deficiência do ácido graxo ômega-3 pode 
ter um papel interessante neste cenário. Alguns estudos animais e clínicos têm sugerido que os ácidos graxos ômega-3 
podem ser úteis na prevenção e no tratamento da epilepsia e, consequentemente, na SUDEP. Os únicos alimentos que 
contêm grandes proporções de ômega-3 são os frutos do mar (peixes e mariscos). No entanto, alguns peixes podem 
estar contaminados com metilmercúrio, o que pode levar a um efeito contrário ao benefício trazido pelos ácidos graxos 
ômega-3. Aqui, resumimos o conhecimento do papel do consumo de peixe nas pesquisas em epilepsia.
Palavras-chave: epilepsia, ômega-3, coração, morte súbita, consumo de peixe.
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1. Sudden Unexpected Death in Epilepsy: 
General View
Epilepsy is one of the most common neurologic 
problems worldwide (Chang and Lowenstein, 2003). 
Approximately 2 million people in the United States have 
epilepsy, and 3 percent of people in the general population 
will have epilepsy at some point in their lives (Chang and 
Lowenstein, 2003). Prevalence in Brazil was determined in 
small populations and is about 8.2/1.000 inhabitants (Borges 
et al., 2004). Unfortunately, individuals with epilepsy 
are at higher risk of death than the general population 
and sudden unexpected death in epilepsy (SUDEP) is 
the most important direct epilepsy-related cause of death 
(Stollberger and Finsterer, 2004). SUDEP is responsible for 
7.5 to 17% of all deaths in epilepsy and has an incidence 
among adults between 1:500 and 1:1,000 patient-years 
(Schuele et al., 2007). SUDEP is defined by precise 
criteria that were approved in 1997 by an expert panel 
and is designated as sudden, unexpected, witnessed or 
unwitnessed, non-traumatic and non-drowning deaths in 
patients with epilepsy, with or without evidence of a seizure 
and excluding documented status epilepticus, in which 
post mortem examination does not reveal a toxicological 
or anatomical cause of death (Nashef, 1997).
A number of associated factors for SUDEP have 
been reported but the results are not wholly consistent 
between studies. These include refractoriness of the 
epilepsy, presence of generalised tonic-clonic seizures, 
polytherapy with antiepileptic drugs, young age, duration 
of the seizure disorder ranging from 15 to 20 years, early 
onset of epilepsy and winter temperatures (Stollberger and 
Finsterer, 2004; Scorza et al., 2007). Additionally, potential 
pathomechanisms for SUDEP are unknown, but it is very 
probable that cardiac arrhythmia during and between 
seizures plays a potential role (Stollberger and Finsterer, 
2004). Over the past two decades, important advances have 
been made concerning SUDEP. However, our understanding 
of the exact mechanisms underlying SUDEP and the best 
way to prevent it, are still incomplete.
2. Possible Cardiac Abnormalities Related to 
Sudden Unexpected Death in Epilepsy
A better understanding of the mechanisms of SUDEP 
is essential. As already discussed, the cause of death in 
SUDEP is currently unknown; however, a number of 
postmortem, ictal and interictal cardiac abnormalities account 
for the possibility of seizure-induced cardiogenic SUDEP 
(Stollberger and Finsterer, 2004; Ryvlin et al., 2006).
Postmortem examinations: In some SUDEP patients, a 
dilated and heavier than expected heart was found (Stollberger 
and Finsterer, 2004; Bell and Sander, 2006; Colugnati 
et al., 2005). Furthermore, pathological alterations in the 
heart of SUDEP cases have also been described, such as 
fibrosis of the walls of small coronary arteries, atrophy 
of cardiomyocytes, myofibrillar degeneration, edema of 
the conductive tissue and morphological abnormalities of 
the cardiac conduction system (Stollberger and Finsterer, 
2004; Bell and Sander, 2006; Colugnati et al., 2005). 
These abnormalities may be the consequence of repeated 
hypoxemia and/or an associated increase of catecholamines 
during ictal sympathetic storm (Stollberger and Finsterer, 
2004; Bell and Sander, 2006; Colugnati et al., 2005).
Ictal period: Several studies have assessed the frequency 
and character of ictal cardiac rhythm during seizures 
(Stollberger and Finsterer, 2004; Ryvlin et al., 2006; 
Lathers et al., 2008) and compelling evidence exists for 
the presence of ictal arrhythmias (Ryvlin et al., 2006). 
For instance, Nashef et al. (1996) recorded non-invasively 
ictal cardiorespiratory variables in patients with epilepsy. 
They found an increase in heart rate in 91% of 41 seizures 
monitored, and a transient bradycardia in five seizures 
(four patients). Moreover, Nei et al. (2000) evaluated the 
electrocardiographic (ECG) changes in fifty-one seizures 
in 43 patients with refractory epilepsy. They showed that 
seventy percent of patients had either ECG abnormalities 
(16%) or tachycardia (30%) or both (23%) during the 
ictal and/or post-ictal period. All authors suggest that 
these changes may be relevant to the pathophysiology 
of SUDEP.
Interictal period: Cardiac investigations between 
seizures have been described by several research groups. 
Drake et al. (1993) reviewed resting ECGs in 75 patients 
with epilepsy and compared ventricular rate, PR interval, 
QRS duration, and QT interval corrected for heart rate 
(QTC) with normal ECGs recorded in age-matched patients 
without cardiac or neurologic disorders. Epilepsy patients 
showed a higher heart rate and a longer QT duration than 
ECGs recorded in age-matched patients without a cardiac 
or neurologic disorder. However, heart rate and QT duration 
were not outside the normal range. In 2003, Tigaran et al. 
(2003) investigated whether patients with drug refractory 
epilepsy have cardiovascular abnormalities that might 
be related to a high frequency of sudden death. In their 
study, twenty-three patients underwent comprehensive 
cardiovascular evaluations (ECG, Holter-monitoring, 
echocardiography, ergometric exercise test and myocardial 
scintigraphy, and, if abnormalities were found, coronary 
angiography) before and during video-EEG monitoring. 
They found ST-segment depression in 40% of patients, 
which were associated with a higher maximum heart rate 
during seizures, suggesting that cardiac ischemia may occur 
in these patients (Tigaran et al., 2003). Although interictal 
changes in heart rate variability have been described in 
patients with epilepsy, their contribution to SUDEP remains 
to be determined (Tomson et al., 2008).
3. The Potential Role of Omega-3 in the 
Management of Epilepsy
Beneficial effects of omega-3 fatty acids on the 
cardiovascular system have been postulated. Several 
studies have shown that omega-3 fatty acids have protective 
effects in preventing coronary heart disease, reducing 
arrhythmias and thrombosis, lowering plasma triglyceride 
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levels and reducing blood clotting tendency (Smith and 
Sahyoun, 2005). Furthermore, substantial evidence from 
epidemiological and case-control studies indicates that 
omega-3 reduces the risk of cardiovascular mortality, 
with an especially potent effect on sudden cardiac death 
(Calder, 2004).
Concerning epilepsies, although the availability of 
pharmacological treatment of this neurological condition 
has expanded, antiepileptic drugs are still limited in clinic 
efficacy. Several genetic, environmental and social factors 
can contribute to the inefficacy of therapeutic outcomes 
in patients with epilepsy. Among these factors, nutritional 
aspects, i.e., omega-3 fatty acids deficiency may have an 
interesting role. Some animal and clinical studies have 
indicated that omega-3 fatty acids could be useful in the 
prevention/treatment of epilepsy, as well as having a possible 
effect in the prevention of cardiovascular abnormalities and 
a reduction of occurrence of SUDEP (Taha et al., 2009; 
Scorza et al., 2008; DeGiorgio et al., 2008).
In 1998, Voskuyil and colleagues, using the cortical 
stimulation seizure model in rats, demonstrated a modest 
anticonvulsant effect with a long duration as a result of the 
administration of polyunsaturated fatty acids. Moreover, 
pharmacology studies show that polyunsaturated fatty acids 
applied extracellularly raise the stimulatory thresholds of 
CA1 neurons in hippocampal slices (Xiao and Li, 1999). 
Recently, our group was the first to demonstrate that a 
chronic treatment with omega-3 fatty acids promoted 
neuroprotection and increased parvalbumin-positive 
neurons in the hippocampal formation of rats with epilepsy 
(Ferrari et al., 2008), suggesting that omega-3 fatty acids 
administration leads to prominent positive plastic changes 
in the hippocampal formation of rats with epilepsy. In 
this line, Puri et al.(2007) demonstrated a decrease in 
phosphodiesters in patients with epilepsy supplemented 
with omega-3. In a clinical study, Schlanger et al. (2002) 
reported on an open trial in which 5 patients took omega-3 
supplements. In that study, a special spread containing 
65% omega-3 fatty acids was added to the daily diet of 
five patients with epilepsy. The patients consumed 5 g 
of this spread at every breakfast for 6 months and all of 
them showed a marked reduction in both frequency and 
strength of epileptic seizures, suggesting that a dietary 
supplement containing omega-3 may be beneficial for the 
suppression of some cases of epileptic seizures. Recently 
the first randomized, placebo-controlled parallel trial of 
omega-3 supplementation in 57 patients with refractory 
epilepsy, seizure frequency was reduced over the first 
6 weeks of treatment in the supplemented group, but this 
effect was not sustained over the 12 week total trial (Yuen 
and Sander, 2004). The authors believe that the loss of 
effect following the initial 6 weeks is a result of omega-3 
preparations, doses, treatment duration, and sample sizes. 
Specifically, the researchers used in their study a total 
daily dose of approximately 1.7 g omega-3 (approx 1 g 
eicosapentaenoic acid (EPA) and 0.7g docosahexaenoic 
acid (DHA)), but believe that higher doses and different 
omega-3 ratios should be tested.
As omega-3 fatty acids per se have been shown in 
some studies to reduce cardiac arrhythmias and sudden 
cardiac deaths (Calder, 2004), Yuen and Sander (2004) 
proposed the interesting hypothesis that omega-3 fatty acid 
supplementation in patients with refractory seizures may not 
only reduce seizures but also reduce cardiac arrhythmias 
and hence SUDEP. Two experimental studies developed by 
our group could better reinforce this hypothesis. Firstly, we 
evaluated the heart rate, in vivo (ECG) and isolated ex vivo 
preparation (Langendorf preparation) of rats with epilepsy 
(Colugnati et al., 2005). Our results showed significant 
differences in the mean heart rate in vivo between the 
groups. In contrast, we did not find differences in the 
isolated ex vivo situation, suggesting a central nervous 
system modulation of the heart, which could explain sudden 
unexpected death in epilepsy. Scorza et al. (unpublished 
data) performed a similar set of experiments (heart rate 
in vivo and isolated ex vivo preparation) of rats with 
epilepsy before and after chronic omega-3 administration. 
The results showed differences in the mean heart rate in 
vivo, but surprisingly, no differences in heart rate could 
be observed in the isolated ex vivo condition.
It has been suggested that the use of certain antiepileptic 
drugs (AEDs), especially carbamazepine (CBZ), may give 
rise to a predisposition to SUDEP (Stollberger and Finsterer, 
2004). Furthermore, CBZ has been shown to affect the 
autonomic nervous system and the conduction system of 
the heart, mainly when associated with elevated plasma 
drug levels above 40 µmol.L–1 (Stollberger and Finsterer, 
2004). According to this, Yuen et al. (2008) reported 
very recently the fatty acid (FA) profiles in red blood 
cells (RBCs) and plasma obtained prior to and following 
omega-3 FA supplementation in 56 patients with epilepsy, 
providing an opportunity to examine potential effects of 
AEDs on FA profiles. They showed that patients on CBZ 
exhibited a less favorable FAs profile, associated with a 
greater risk of coronary heart disease mortality. In sum, the 
authors concluded that as arrhythmias are thought to be an 
important mechanism in coronary heart disease mortality 
and sudden unexplained death in epilepsy (SUDEP), the 
effect of CBZ effect in reducing omega-3 FAs might 
potentially explain some cases of SUDEP among patients 
prescribed CBZ.
Taking all data together, the first randomized, placebo-
controlled parallel group study of omega-3 supplementation 
in patients with chronic epilepsy showed only a transient 
effect on seizure frequency that was not confirmed by 
another research group, but additional trials are required 
(Scorza et al., 2008; DeGiorgio and Miller, 2008). These 
results did not totally confirm that omega-3 fatty acids 
reduce the frequency of epileptic seizures in patients with 
intractable epilepsy; however, they established the safety 
of omega-3 supplementation in people with epilepsy 
(DeGiorgio and Miller, 2008). Quite interestingly, there is 
now great interest in n-3 fatty acids for the prevention of 
SUDEP (Scorza et al., 2008; DeGiorgio and Miller, 2008) 
and we have to bear in mind that as omega-3 fatty acids 
per se have been shown to reduce cardiac arrhythmias and 
sudden cardiac deaths, it could be suggested that omega-3 
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fatty acid supplementation in patients with refractory 
seizures may reduce seizures and seizure-associated 
cardiac arrhythmias and hence SUDEP. However, it is 
very important to emphasize that nutritional therapy 
(e.g., omega-3 supplementation) is not a substitute for 
anticonvulsant medications.
4. Polyunsaturated Fatty Acids in the Diet
Polyunsaturated fatty acids are present at high levels in 
the brain (Ohara, 2007). The 04 polyunsaturated fatty acids 
are designated eicopentanoic acid (EPA) and decosahexanoic 
acid (DHA), which are n-3 fatty acids (omega-3); and 
dihomogammalinolenic acid (DGLA) and arachidonic 
acid (AA), which are n-6 fatty acids (omega-6), comprise 
over 10% (w/w) of the dry weight of the brain (Ohara, 
2007; Calon and Cole, 2007).Fish and fish oil long chain 
omega-3 fatty acids may interfere with certain nervous 
system diseases (Ferrari et al, 2008; Bourre, 2004). Omega-3 
fatty acids are important for the treatment and prevention 
of cardiovascular and neurological diseases, and a diet rich 
in fish may be a good way to improve the development 
of the brain (Table 1) (Ferrari et al, 2008; Bourre, 2004). 
The only foods that provide large amounts of omega-3 are 
seafood (fish and shellfish – Figure 1).
Undeniably, fish is very good for us. However, some 
kinds of fish contain    contaminants such as methylmercury 
(Smith, 2005; Jeejeebhoy, 2008; Clarkson and 2003) that 
is strongly neurotoxic, specially for infants (Smith and 
Sahuoun, 2005; Jeejeebhoy, 2008; Clarkson et al, 2003). 
Considering this, the consumption of non predatory fish 
should be the best choice (Jeejeebhoy, 2008; no authors, 2007) 
(Table 2). Taking into account species usually consumed 
in Brazil, sardines should be considered the first choice, 
because of its low methyl mercury concentration.
5. Final Considerations
The risk of sudden death is clearly greater in the 
epilepsy population, and SUDEP is the commonest seizure-
related category (Stollberger and Finsterer, 2004; Tomson 
et al., 2008; Scorza et al., 2008; Yuen and Sander, 2004). 
Figure 1. Top 13 fish and shell fish rich in omega-3 fatty 
acids.Table 1. Safe and effective doses of omega-3 fatty acids for 
adults. Adapted by permission from Dr. Marianna Mazza.
EPA and DHA
• The adequate daily intake of EPA and DHA for 
adults should be at least 220 mg of each per day.
• Two to three servings of fatty fish per week (roughly 
1250 mg EPA and DHA per day) are generally 
recommended to treat psychiatric and neurological 
disorders.
Fish oil supplements
• 3000 to 4000 mg standardised fish oils per day (this 
amount corresponds to roughly 2 to 3 servings of fatty 
fish per week).
• Typically, a 1000 mg fish oil capsule has 180 mg 
EPA and 120 mg DHA.
Table 2. Top 13 fish and shell fish rich in omega-3 fatty 
acids considering methyl mercury concentration.
Methyl mercury concentration
Low High
Anchovies King Mackerel
Lobster Shark
Mussels Swordfish
Salmon Tilefish
Sardines Tuna
Scallops -
Shrimp -
Trout -
Furthermore, SUDEP is mainly, but not exclusively, a 
problem for patients with chronic uncontrolled epilepsy 
(Stollberger and Finsterer, 2004; Tomson et al., 2008). In 
this sense, the ultimate goal of research in SUDEP is to 
develop new methods to prevent it, alongside actions other 
than medical and surgical therapies, which could be very 
useful in this scenario. At present, a number of different 
dietary modifications and nutritional supplements may 
help prevent seizures or improve other aspects of health in 
patients with epilepsy (McElroy-Cox, 2009; Gaby, 2007; 
Schlanger et al., 2002). In particular, our group is quite 
convinced that omega-3 fatty acids are very important for 
the normal functioning of the brain and more than this, 
in patients with refractory epilepsy, they may help reduce 
seizures and seizure-associated cardiac arrhythmias and 
hence, SUDEP.
Finally, fish is one of the most important foods we can 
choose for cardiovascular and brain health. The type of 
fish and seafood, the frequency of consumption, and the 
meal size are all essential issues in the balance of benefits 
and risks of regular consumption (Domingo, 2007). On 
the other hand, for individuals who want a diet with zero 
methylmercury but would like to enjoy the benefits of 
omega-3 fatty acids, there are always fish oil supplements 
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or intake of foods such as walnuts or oils (flax, canola and 
soybean) (Jeejeebhoy, 2008; Domingo, 2007).16,275
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